Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS

                                                                  

Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression.

Currently in late preclinical development, NDC-1308 is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause of neurodegenerative disorders like MS. The therapy is specifically targeted to heal motor neuron damage, and is intended for use either as a monotherapy or in combination with other disease-modifying agents to slow progression.

Remyelination is the process of coaxing oligodendrocyte precursor cells (OPCs) to form oligodendrocytes, cells able to produce new myelin sheaths on demyelinated axons in the central nervous system (CNS). This is a process naturally regulated in the body and tends to be very efficient in a healthy CNS. But in people with MS, remyelination becomes increasingly incomplete and in many patients eventually fails, leading to more progressive disease forms.

NDC-1308 works on a chain of key regulatory gene pathways responsible for the differentiation of OPCs and myelin synthesis. In preclinical models, it has been shown to effectively cross the blood-brain barrier, and to exert its effects on motor neurons in the brain and spinal cord.

READ more on this Remyelination hope

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews